Detalhe da pesquisa
1.
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells.
Nature
; 602(7897): 503-509, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35110735
2.
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.
Nature
; 558(7709): 307-312, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29849141
3.
Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells.
Mol Ther
; 31(8): 2309-2325, 2023 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37312454
4.
Author Correction: Decade-long leukaemia remissions with persistence of CD4+ CAR T cells.
Nature
; 612(7941): E22, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36477542
5.
A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells.
Blood
; 135(7): 505-509, 2020 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31703119
6.
Mechanisms of resistance to CAR T cell therapies.
Semin Cancer Biol
; 65: 91-98, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31866478
7.
Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy.
Blood
; 134(1): 44-58, 2019 07 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31076448
8.
Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.
Mol Ther
; 28(11): 2367-2378, 2020 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32730744
9.
Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma.
Blood
; 132(10): 1022-1026, 2018 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29925499
10.
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
Mol Ther
; 27(11): 1919-1929, 2019 11 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31420241
11.
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.
Gastroenterology
; 155(1): 29-32, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29567081
12.
Do CARs finally hit the CLL road?
Blood
; 139(12): 1775-1776, 2022 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35323881
13.
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.
Blood
; 130(21): 2317-2325, 2017 11 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28935694
14.
Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients.
Mol Ther
; 26(1): 269-279, 2018 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29203150
15.
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.
N Engl J Med
; 373(11): 1040-7, 2015 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26352815
16.
Toward precision manufacturing of immunogene T-cell therapies.
Cytotherapy
; 20(5): 623-638, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29653875
17.
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
Crit Care Med
; 45(2): e124-e131, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27632680
18.
CAR-T and ibrutinib vs CLL: sequential or simultaneous?
Blood
; 135(19): 1611-1612, 2020 05 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32379875
19.
Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome.
Blood
; 136(17): 1980-1983, 2020 10 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-32518951
20.
B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy.
Br J Haematol
; 193(4): 851-855, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33713436